Anaplastic large cell lymphoma (ALCL) is one of the most common T-cell non-Hodgkin lymphomas and has 2 main subtypes: an anaplastic lymphoma kinase (ALK)-positive subtype characterized by ALK gene rearrangements and an ALK-negative subtype that is poorly understood. We recently identified recurrent rearrangements of the DUSP22 locus on 6p25.3 in both primary cutaneous and systemic ALK-negative ALCLs. This study aimed to determine the relationship between these rearrangements and expression of the chemokine receptor gene, CCR8. CCR8 has skin-homing properties and has been suggested to play a role in limiting extracutaneous spread of primary cutaneous ALCLs. However, overexpression of CCR8 has also been reported in systemic ALK-negative ALCLs. As available antibodies for CCR8 have shown lack of specificity, we examined CCR8 expression using quantitative real-time PCR in frozen tissue and RNA in situ hybridization (ISH) in paraffin tissue. Both approaches showed higher CCR8 expression in ALCLs with DUSP22 rearrangements than in nonrearranged cases (PCR: 19.5-fold increase, P = 0.01; ISH: 3.3-fold increase, P = 0.0008). CCR8 expression was not associated with cutaneous presentation, cutaneous biopsy site, or cutaneous involvement during the disease course. These findings suggest that CCR8 expression in ALCL is more closely related to the presence of DUSP22 rearrangements than to cutaneous involvement and that the function of CCR8 may extend beyond its skin-homing properties in this disease. This study also underscores the utility of RNA-ISH as a paraffin-based method for investigating gene expression when reliable antibodies for immunohistochemical analysis are not available.
A naplastic large cell lymphomas (ALCLs) are among the most common T-cell non-Hodgkin lymphomas and comprise several subtypes that demonstrate overlapping morphologic and immunophenotypic characteristics but vary in clinical and genetic features. The World Health Organization (WHO) classification of hematopoietic neoplasms recognizes 3 distinct entities: primary cutaneous ALCL (pcALCL); anaplastic lymphoma kinase (ALK)-positive ALCL; and, provisionally, ALK-negative ALCL. [1] [2] [3] The latter 2 entities are systemic diseases and are distinguished from each other only by the presence or absence, respectively, of chromosomal rearrangements involving the ALK gene on 2p23.2. In contrast, pcALCL arises in the skin, typically does not disseminate systemically, and is ALK-negative in most cases. Although ALK rearrangements play a key role in the pathogenesis of ALK-positive ALCL, 4 little has been known about the genetics and pathogenesis of systemic ALK-negative ALCL and pcALCL.
Using next-generation sequencing and complementary approaches, we recently discovered and characterized recurrent chromosomal rearrangements involving the DUSP22-IRF4 locus on 6p25.3 (DUSP22 rearrangements) that occur almost exclusively in ALK-negative ALCLs, including both pcALCLs and systemic ALK-negative ALCLs. [5] [6] [7] Although the biologic consequences of these rearrangements have not been established, preliminary data using gene expression profiling (GEP) suggested that cases with DUSP22 rearrangements demonstrated increased expression of the chemokine (C-C motif) receptor 8 (CCR8) gene. 8 CCR8 also has been reported to be overexpressed in pcALCL compared with cases of primary cutaneous peripheral T-cell lymphoma, not otherwise specified (pcPTCL, NOS). 9 It was proposed that, because of the skin-homing properties of CCR8, this finding might explain the decreased tendency for pcALCL to spread extracutaneously compared with pcPTCL, NOS. Interestingly, however, CCR8 expression also has been reported to be elevated in systemic ALK-negative ALCLs. 10 Because both pcALCL and systemic ALK-negative ALCL may carry DUSP22 rearrangements (which we did not identify in a study of 25 cases of pcPTCL, NOS 6 ), we sought to determine whether the cutaneous involvement or the DUSP22 rearrangement status was more closely associated with increased CCR8 expression in ALCLs.
MATERIALS AND METHODS

Patients
Patients were identified from the hematopathology practices at Mayo Clinic, Rochester, MN (n = 44) and United Health Services Hospitals, Johnson City/ Binghamton, NY (n = 6). All patients had ALCL as classified by WHO criteria, 11 had sufficient clinical data available for subclassification as pcALCL or systemic ALCL, and had formalin-fixed, paraffin-embedded tissue and/or frozen tissue available. Follow-up data were obtained when possible from the medical record to identify potential secondary skin involvement in patients with systemic disease. Research was conducted under protocols approved by the Institutional Review Boards of Mayo Clinic and United Health Services Hospitals.
Immunohistochemistry and Fluorescence In Situ Hybridization (FISH)
Immunohistochemical analysis was performed on paraffin tissue sections as part of the diagnostic evaluation or subsequently using methods, antibodies, and conditions described previously. 12, 13 We were unable to evaluate CCR8 expression by immunohistochemical analysis because of lack of specificity of available antibodies in our experience and as previously published by others. [14] [15] [16] DUSP22 rearrangement status based on break-apart FISH for the DUSP22-IRF4 locus was available from previous studies in a subset of the cases and was determined in additional cases as previously described. [5] [6] [7] Quantitative Real-time Polymerase Chain Reaction (qRT-PCR) qRT-PCR was performed in samples for which frozen tumor tissue was available using previously described methods with minor modifications. 7 Briefly, total RNA was extracted from frozen tumor tissue specimens using PerfectPure (5 PRIME, Gaithersburg, MD) and converted to cDNA using the High Capacity Reverse Transcription kit (Applied Biosystems, Foster City, CA). The CCR8 primer/probe set was obtained from Applied Biosystems (Assay ID, Hs00174764_m1). The GAPDH primer/probe set was described previously. 7 qRT-PCR was performed in duplicate on a 7900HT Fast Real-Time PCR System (Applied Biosystems). Expression levels for each gene were compared with standard curves obtained from serially diluted reference standards, and CCR8 expression was normalized to GAPDH expression.
RNA In Situ Hybridization (RNA-ISH)
For ISH, RNA probes (RNAscope; Advanced Cell Diagnostics, Hayward, CA) were obtained for CCR8, UBC (ubiquitin C; positive control), and dapB (negative control). Four-micrometer-thick paraffin-embedded tissue sections were deparaffinized in xylene, rehydrated in graded ethanol concentrations, and pretreated in citrate buffer (pH 8.0) for 15 minutes at 981C. Sections were then treated with protease for 5 minutes at room temperature and incubated at 401C with probe for 2 hours. Signal was visualized by incubating sections sequentially with preamplifier, amplifier, and horseradish peroxidase-labeled probes, followed by color development with diaminobenzidine, using RNAscope 2.0 Brown Reagent kit (Advanced Cell Diagnostics) according to the manufacturer's instructions.
Digital Image Analysis (DIA)
For each sample, corresponding areas were circled on the CCR8 and UBC slides that contained predominantly tumor cells, had visible signal on the UBC-positive control, and had minimal or no signal on the dapB-negative control. Slides were scanned digitally at Â 40 magnification and 4096Â 64 pixel resolution using the NanoZoomer Digital Pathology System (Hamamatsu, Bridgewater, NJ). The circled areas of the CCR8 and UBC slides were used to select regions of interest (ROIs) to be analyzed and ISH signals were quantified using an algorithm for threshold detection from commercially available Tissue Studio software (Definiens, Munich, Germany). Signal then was expressed as the percentage of total area threshold by calculating the ratio of pixels thresholded to total pixels in each ROI.
Statistical Analysis
Values were expressed as means ± SD. Significance levels were analyzed using the Wilcoxon test, the Spearman correlation, or the w 2 test, as appropriate, using the JMP Pro 9.0.1 (SAS Institute, Cary, NC).
RESULTS
Patient Characteristics
There were 50 patients in the study, including 29 men and 21 women with a mean age of 60 years (range, 12 to 89 y; Table 1 ). Diagnoses included systemic ALK-positive ALCL in 6 patients, systemic ALK-negative ALCL in 28, and pcALCL in 16. DUSP22 rearrangements were present in 24 patients and absent in 26. DUSP22 rearrangement status was not significantly associated with sex. Of the 24 cases with DUSP22 rearrangements, 12 were systemic ALK-negative ALCLs and 12 were pcALCLs; as previously reported, DUSP22 rearrangements were not seen in ALK-positive ALCLs. 5, 6 The specimens tested were obtained from a noncutaneous site in 32/33 systemic ALCLs and from a cutaneous site in 13/16 pcALCLs.
qRT-PCR Evaluation of CCR8 Expression in ALCL
To validate previous GEP data, we performed qRT-PCR on cDNA prepared from whole sections of frozen ALCL tissues. Expression of CCR8 was normalized to that of GAPDH and expressed as fold change compared with the mean value of cases without DUSP22 rearrangements. CCR8 expression was 19.5 ± 16.1 in ALCLs with DUSP22 rearrangements compared with 1.0 ± 2.0 in nonrearranged cases (ie, 19.5-fold higher, P = 0.01; Fig. 1A ). No significant difference in CCR8 expression was observed when cases were stratified by ALCL subtype (Fig. 1B ). In keeping with previously published data, there was a trend toward lower expression in ALK-positive ALCL (0.2 ± 0.2) than in ALK-negative ALCL (3.9 ± 7.9) or pcALCL (11.4 ± 17.6); however, this trend was primarily attributable to the cases with DUSP22 rearrangements. Taken together, these findings were in concordance with previous GEP data and suggested a relationship between DUSP22 rearrangements and CCR8 expression; however, the sample size was small and it was not possible to determine whether the CCR8 expression detected was derived from tumor cells specifically. Thus, we examined CCR8 expression in tissue sections from additional cases.
RNA-ISH Evaluation of CCR8 Expression in ALCL
As discussed above, we were unable to assess CCR8 expression by immunohistochemical analysis because of lack of specific antibodies. Therefore, we examined CCR8 expression by RNA-ISH in paraffin tissue sections. We performed DIA of selected areas of the sections rich in tumor cells and showed appropriate staining for the positive and negative controls, UBC and dapB, respectively. CCR8 expression, as measured by the percent thresholded area in the selected portion of the tissue, was 9.8 ± 6.7 in ALCLs with DUSP22 rearrangements compared with 2.9 ± 3.9 in those without translocations (ie, 3.3-fold higher, P = 0.0003; Fig. 2A ). Although only a small number of patients had data for both qRT-PCR and RNA-ISH, there was a trend toward an association between these values, despite the differences in specimen type (frozen vs. paraffin) and sampling (whole section vs. selected area; Spearman r = 0.47, P = 0.09; data not shown).
As all tumors were subjected to RNA-ISH for the UBC-positive control, we also performed DIA of the corresponding areas on these slides to investigate potential contributions of variation in UBC staining to the results. UBC expression was similar in ALCLs with DUSP22 rearrangements (21.3 ± 12.7) and those without rearrangements (20.8 ± 12.2; P = 0.99; Fig. 2B ). Using the CCR8/ UBC expression ratio yielded results similar to those obtained with using CCR8 expression alone. This ratio was 0.54 ± 0.42 in ALCLs with DUSP22 rearrangements compared with 0.17 ± 0.21 in those without rearrangements (ie, 3.2-fold higher, P = 0.0006; Fig. 2C ).
CCR8 Expression and Clinicopathologic Features of ALCL
ALCLs in this study had pathologic features typical for this entity (Figs. 3, 4 ). All had characteristic hallmark cells noted on hematoxylin and eosin stains and demonstrated uniform staining for CD30. CCR8 expression as visualized by RNA-ISH was almost entirely limited to tumor cells, and prominent staining was not observed in other areas of the sections, suggesting that differences observed by GEP and qRT-PCR were because of expression of CCR8 by tumor cells specifically. Break-apart FISH for the DUSP22-IRF4 locus on 6p25.3 was successful in determining DUSP22 rearrangement status in all cases (Table 1) .
Because CCR8 is a chemokine receptor that has been implicated in skin homing, we investigated whether CCR8 expression was associated with ALCL subtype; biopsy site (cutaneous vs. extracutaneous); or presence of skin involvement at any time in the patient's disease course. Although these analyses are related, they are not identical, as systemic ALCL can secondarily involve the skin and primary cutaneous ALCL can secondarily involve extracutaneous sites. 17 None of these analyses demonstrated statistically significant differences (Fig. 5 ). Again, a trend toward lower CCR8 expression in ALKpositive ALCLs was observed Fig. 5A ). CCR8 expression was 7.0 ± 6.8 in ALK-negative ALCL, 1.7 ± 1.6 in ALKpositive ALCL, and 8.0 ± 6.7 in pcALCL. CCR8 expression was 8.8 ± 6.4 in skin biopsy specimens of ALCLs and 6.4 ± 6.8 in extracutaneous biopsy specimens of ALCL (Fig. 5B) . By definition, all 12 patients with pcALCL had skin involvement. Among 26 ALCLs pre- senting with systemic disease, follow-up data were available in 19, with a median follow-up time of 28 months (range, 1 to 207 mo). Of these 19 patients, 2 developed secondary cutaneous disease (at 1 and 19 mo after diagnosis, respectively), both of which were ALK-negative ALCLs lacking DUSP22 rearrangements. Considering pcALCLs and systemic ALCLs together, CCR8 expression was 7.0 ± 6.6 in ALCLs with skin involvement at any time in their disease course and 6.3 ± 7.1 in ALCLs without skin involvement (Fig. 5C ).
DISCUSSION
In the present study, we have demonstrated that the chemokine receptor gene, CCR8, is overexpressed in ALCLs with DUSP22 rearrangements. This is the first tissue-based study to provide insight on biologic features associated with this rearrangement. Importantly, the findings suggest that CCR8 expression in ALCL is more closely related to the presence of DUSP22 rearrangements than to cutaneous involvement. These data raise the possibility that the function of CCR8 may extend beyond its skin-homing properties in this disease.
Chemokines and chemokine receptors play a crucial role in mediating the migration of target cells to specific tissues and are involved in a variety of biological processes under both physiologic and pathologic conditions. 18, 19 Dermal microvessels and epidermal antigen-presenting cells express the CCR8 ligand, CCL1, which plays a role in regulating cutaneous migration of CCR8-positive immune surveillance T cells. 20 van Kester et al 9 have shown that CCR8 expression is higher in pcALCLs than in pcPTCL, NOS, and suggested that this expression (along with that of the related chemokine receptor gene, CCR10) might explain the lower tendency of pcALCL to disseminate to extracutaneous sites. Interestingly, even when pcALCL does exhibit extracutaneous spread, dissemination tends to be limited. Typically, only locoregional lymph nodes are involved, and outcomes in these cases are similar to those of pcALCLs limited to the skin. 17 Of note, lymphatic endothelial cells in lymph node sinuses express CCL1, and CCR8 expression is critical in lymph node migration of both monocyte-derived dendritic cells and melanoma cells. 21, 22 Finally, CCR8/CCL1 interactions, as well as newly described CCR8/CCL18 interactions, have been implicated in T-cell homing to several other extracutaneous sites, including the esophagus, pancreatobiliary system, and lungs. 15, 23, 24 Taken together, these findings suggest the possibility that the role of CCR8 in ALCL extends beyond the cutaneous microenvironment.
DUSP22 rearrangements and ALK rearrangements are the 2 most common chromosomal rearrangements reported in ALCL, and studies to date have found them to be mutually exclusive. [5] [6] [7] 25 The breakpoints within the DUSP22-IRF4 locus on 6p25.3 may vary; irrespective of breakpoint, however, these cases share the feature of marked downregulation of DUSP22 expression without alterations in IRF4 expression. 7 DUSP22 is a dual-specificity phosphatase involved in modulating mitogen-activated protein kinase activity and specifically has been shown to inhibit T-cell receptor signaling. 26, 27 Although early data suggested that DUSP22 rearrangements were seen mostly in pcALCL, our subsequent studies have shown nearly the same frequency in systemic ALK-negative ALCLs. [5] [6] [7] Interestingly, increased CCR8 expression has been reported not only in pcALCL but also in systemic ALK-negative ALCL. 10 The additional finding that ALCLs with DUSP22 rearrangements showed increased CCR8 expression in a small pilot study using GEP prompted us to perform the current study. 8 Our findings conclusively demonstrate a significant association between CCR8 expression and DUSP22 rearrangements. No significant association was found between CCR8 and cutaneous presentation, cutaneous site of biopsy, or cutaneous involvement at any time in the disease course. These findings raise the possibility that the previously reported increases in CCR8 expression in pcALCL or systemic ALK-negative ALCL may have been due in part to the presence of DUSP22 rearrangements in subsets of the cases analyzed; however, the DUSP22 rearrangement status of those cases is unknown. Also unknown is whether our findings have implications for the rare reported cases of ALK-positive pcALCL. Although not included in the present series, we have examined 2 such cases by FISH and both lacked DUSP22 rearrangements (ALF, unpublished data). The finding that DUSP22 rearrangement is more strongly associated with CCR8 expression than cutaneous site should not be taken as evidence against the proposal by van Kester and colleagues that CCR8 contributes to the more limited dissemination of pcALCL than pcPTCL, NOS. Rather, the possibility exists that the role of CCR8 in regulating migration of ALCL cells may extend beyond cutaneous sites. Indeed, systemic ALK-negative ALCL also has a clinical course significantly more favorable than systemic PTCL, NOS, and the biologic basis for this difference remains unclear. 28 Furthermore, early data have suggested that DUSP22 rearrangements identify a group of patients with prognosis even better than that of other systemic ALK-negative ALCLs. 29 Finally, we also recently identified DUSP22 rearrangements in a subset of patients with lymphomatoid papulosis, an indolent cutaneous T-cell neoplasm with excellent prognosis (although, to our knowledge, expression of CCR8 in this disease is unknown). 30 Taken together, these findings suggest an association among DUSP22 rearrangement, CCR8 expression, and relatively favorable clinical outcomes. This clinical behavior might be related to homing signals, including expression of CCR8, that prevent more aggressive dissemination. It should be noted, however, that the presence of a DUSP22 rearrangements was neither entirely sensitive nor entirely specific for high CCR8 expression; thus, the mechanism responsible for the association between DUSP22 rearrangements and CCR8 expression merits further study. The use of RNA-ISH in this study deserves mention, as analysis of protein expression would be preferable for proposing a hypothesis regarding the potential biologic function of CCR8 in ALCL. However, we and others have found the available CCR8 antibodies to lack specificity and reliability. [14] [15] [16] GEP has identified expression signatures that have played a transformative role in advancing biologic understanding of lymphomas and other diseases. 31 At the individual gene level, however, GEP findings typically have required validation by another method, preferably in tissue sections that allow identification of the cell type with which gene expression is associated. Some gene expression signatures can be examined effectively using immunohistochemical stains, 32 but validated antibodies for immunohistochemical analysis are not available for the majority of genes assayed by GEP. Although RNA-ISH cannot assess protein expression, it shares features with immunohistochemical analysis in that it can be performed in paraffin tissue sections and can be interpreted in the context of tissue architecture and cell type. In addition, it offers the advantage of being relatively easy to develop highly specific probes for virtually any target. Thus, this study underscores the utility of this approach in situations where reliable antibodies are not available.
